Core Viewpoint - Boyuan Co., Ltd. reported a year-on-year increase in revenue for Q3 2025, but experienced a significant decline in net profit [1] Financial Performance - The company's operating revenue for Q3 2025 was 327 million yuan, representing a year-on-year increase of 4.84% [1] - The net profit attributable to shareholders of the listed company was 33.42 million yuan, showing a year-on-year decrease of 31.08% [1] - The net profit attributable to shareholders after deducting non-recurring gains and losses was 30.78 million yuan, reflecting a year-on-year decline of 31.98% [1]

Core Viewpoint - The company announced the adjustment of the Audit Committee members during the second board meeting scheduled for October 23, 2025 [2] Group 1 - The company, Boyuan Co., has convened its second board meeting to discuss the adjustment of the Audit Committee [2]

Group 1 - The core point of the article is that Boyuan Co., Ltd. held its 11th meeting of the second board of directors on October 23, 2025, to discuss the adjustment of the audit committee members [1] - For the year 2024, Boyuan Co., Ltd. reported that its revenue composition is entirely from the chemical industry, with a 100.0% share [1] - As of the time of reporting, Boyuan Co., Ltd. has a market capitalization of 12 billion yuan [1] Group 2 - The article highlights that the Chinese innovative drug sector has generated 80 billion USD in overseas licensing deals this year [1] - It features an interview with Lu Gang, a partner at Chuangdong Investment, discussing the hot secondary market in biomedicine while noting the cooling of fundraising in the primary market [1]

证券代码：301617 证券简称：博苑股份 公告编号：2025-053 山东博苑医药化学股份有限公司 关于使用部分闲置募集资金及自有资金进行现金管理的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 山东博苑医药化学股份有限公司（以下简称"公司"或"博苑股份"）于 2025 年 10 月 23 日召开第二届董事会第十一次会议，审议通过了《关于使用部 分闲置募集资金及自有资金进行现金管理的议案》，同意公司在不影响募集资金 投资项目（以下简称"募投项目"）建设和公司正常经营的情况下，使用不超过 人民币 2.5 亿元（含本数）的闲置募集资金和不超过人民币 5 亿元（含本数）的 闲置自有资金进行现金管理，使用期限自董事会审议通过之日起 12 个月内有效。 在上述额度和期限范围内，资金可循环滚动使用。现将具体情况公告如下： 一、募集资金基本情况 经中国证券监督管理委员会《关于同意山东博苑医药化学股份有限公司首次 公开发行股票注册的批复》（证监许可〔2024〕1415 号）同意注册，博苑股份 首次公开发行人民币普通股（A 股）股票 2,570.00 万股，每股面值 1 ...

Core Insights - The company reported a third-quarter revenue of 327 million yuan, representing a year-on-year increase of 4.84% [1] - The net profit for the third quarter was 33.42 million yuan, showing a year-on-year decline of 31.08% [1] - For the first three quarters, the company achieved a revenue of 1.073 billion yuan, which is a year-on-year growth of 6.60% [1] - The net profit for the first three quarters was 132 million yuan, reflecting a year-on-year decrease of 22.41% [1]

中泰证券股份有限公司 关于山东博苑医药化学股份有限公司使用部分闲置募集资 金及自有资金进行现金管理的核查意见 中泰证券股份有限公司（以下简称"保荐人"）作为山东博苑医药化学股份有 限公司（以下简称"博苑股份"或"公司"）首次公开发行股票并在创业板上市的保 荐人，根据《证券发行上市保荐业务管理办法》《上市公司募集资金监管规则》 《深圳证券交易所创业板股票上市规则》《深圳证券交易所上市公司自律监管指 引第 2 号——创业板上市公司规范运作》等有关法律法规和规范性文件的要求， 对博苑股份使用部分闲置募集资金及自有资金进行现金管理的事项进行了核查， 核查情况及核查意见如下： 一、募集资金基本情况 1 经中国证券监督管理委员会《关于同意山东博苑医药化学股份有限公司首次 公开发行股票注册的批复》（证监许可〔2024〕1415 号）同意注册，博苑股份首 次公开发行人民币普通股（A 股）股票 2,570.00 万股，每股面值 1 元，每股发行 价格为人民币 27.76 元。本次发行募集资金总额为 71,343.20 万元，扣除发行费 用 8,526.43 万元（不含税）后，募集资金净额为 62,816.77 万元。 上述募集 ...

证券代码：301617 证券简称：博苑股份 公告编号：2025-054 山东博苑医药化学股份有限公司 关于调整第二届董事会审计委员会委员的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 山东博苑医药化学股份有限公司（以下简称"公司"）于 2025 年 10 月 23 日召开的第二届董事会第十一次会议，审议通过了《关于调整第二届董事会审计 委员会委员的议案》。 根据《公司法》《上市公司章程指引》等相关规定，为进一步完善公司治理 结构，保障规范运作，健全董事会审计委员会决策机制，提高董事会审计委员会 的监督作用，公司结合实际情况，对第二届董事会审计委员会委员进行了相应调 整。公司董事长李成林先生不再担任公司第二届董事会审计委员会委员职务，李 成林先生辞去审计委员会委员职务后，仍继续担任公司董事职务。公司董事会同 意推选职工代表董事于福强先生为公司第二届董事会审计委员会委员，任期自本 次董事会审议通过之日起至第二届董事会任期届满之日止。 调整后的公司第二届董事会审计委员会委员为：张志红女士、高磊先生、于 福强先生，调整后的审计委员会成员中独立董事占半数以上并由 ...

证券代码：301617 证券简称：博苑股份 公告编号：2025-052 山东博苑医药化学股份有限公司 第二届董事会第十一次会议决议公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 一、董事会会议召开情况 山东博苑医药化学股份有限公司（以下简称"公司"）第二届董事会第十一次 会议通知于 2025 年 10 月 17 日以电子邮件的形式发出，2025 年 10 月 23 日于公 司会议室通过"现场+通讯"的方式召开。本次会议应出席董事 8 人，实际出席 董事 8 人（其中李成林、于国清、王恩训、袁瑞、高磊、张志红、吕志果通过通 讯方式参加会议）。会议由董事长李成林先生召集并主持，公司高级管理人员列 席了会议。会议的通知及召开程序符合相关法律法规和《公司章程》的规定，会 议合法、有效。全体董事审议并通过了如下议案： 二、董事会会议审议情况 1、审议通过《关于公司 2025 年第三季度报告的议案》 公司编制 2025 年第三季度报告的程序符合法律、行政法规和中国证监会的 规定，报告真实、准确、完整地反映了公司经营、管理及财务等各方面的实际情 况，不存在虚假记载、误 ...

Financial Performance - The company's operating revenue for Q3 2025 was ¥326,684,371.22, representing a 4.84% increase compared to the same period last year[5] - The net profit attributable to shareholders for Q3 2025 decreased by 31.08% to ¥33,416,511.08, down from ¥48,575,700.00 in the previous year[5] - The net profit attributable to shareholders after deducting non-recurring gains and losses was ¥30,784,230.00, a decrease of 31.98% compared to ¥45,346,330.00 in the same period last year[5] - The basic earnings per share for Q3 2025 was ¥0.2500, a decline of 60.25% from ¥0.6300 in the previous year[5] - Total operating revenue for the current period reached ¥1,073,470,026.81, an increase of 6.56% compared to ¥1,007,011,836.03 in the previous period[24] - Net profit for the current period was ¥132,459,423.18, a decrease of 22.43% from ¥170,721,927.11 in the previous period[25] - The company reported a total profit of ¥151,232,740.52, down from ¥195,302,327.44 in the previous period[25] - Basic and diluted earnings per share decreased to ¥0.9912 from ¥2.2143 in the previous period[25] Assets and Liabilities - The total assets as of September 30, 2025, were ¥1,875,180,597.22, reflecting a slight decrease of 0.46% from ¥1,883,818,139.55 at the end of the previous year[11] - Total liabilities decreased to ¥186,214,510.10 from ¥227,165,672.67, a decline of about 18%[22] - The total current assets decreased to ¥1,317,759,277.36 from ¥1,378,699,714.08, a decline of approximately 4.4%[21] - The company's cash and cash equivalents decreased to ¥326,802,653.75 from ¥958,580,504.06, representing a decline of approximately 66%[21] - Cash and cash equivalents at the end of the period totaled ¥303,313,498.58, a decrease from ¥278,077,324.63 in the previous period[28] Shareholder Information - Total number of common shareholders at the end of the reporting period is 8,436[15] - The largest shareholder, Li Chenglin, holds 30.40% of shares, totaling 40,625,000 shares[15] - The second largest shareholder, Yu Guoqing, owns 26.51% of shares, amounting to 35,425,000 shares[15] - The third largest shareholder, Zhongmin Tianhe Investment Management Co., holds 9.12% of shares, which is 12,183,340 shares[15] - Wefang Dingju Investment Partnership holds 2.92% of shares, totaling 3,900,000 shares[15] - Jiaxing Lechengyuan Equity Investment Partnership owns 2.14% of shares, amounting to 2,860,000 shares[15] - Wefang Zhishuo Investment Partnership holds 1.95% of shares, totaling 2,600,000 shares[15] - Abu Dhabi Investment Authority owns 1.78% of shares, amounting to 2,373,595 shares[15] - The company reported a total of 1,950,000 shares held by non-state-owned legal entities, representing 1.46% of total shares[16] - The top shareholder, Abu Dhabi Investment Authority, holds 2,373,595 shares of common stock[16] - The second-largest shareholder, Industrial Bank Co., Ltd. - China Aviation New Sailing Flexible Allocation Mixed Securities Investment Fund, holds 1,345,649 shares[16] - The total shares held by the top 10 unrestricted shareholders amount to 5,000,000 shares[16] - The company has not disclosed any changes in the top 10 shareholders due to securities lending or borrowing activities[16] - The report indicates that the company is unaware of any relationships or agreements among the top shareholders[16] - The total number of shares held by the top 10 unrestricted circulating shareholders is 5,000,000 shares[16] - The company has not identified any significant changes in the shareholding structure compared to the previous period[16] Cash Flow and Investments - The net cash flow from operating activities for the year-to-date was -¥30,478,290.54, a significant decline of 124.83% compared to ¥122,730,209.68 in the previous year[10] - The company's investment activities resulted in a net cash outflow of -¥485,319,868.74, a drastic increase of 1221.46% compared to -¥36,726,105.80 in the previous year[13] - Cash flow from operating activities showed a net outflow of ¥30,478,290.54, a significant decline from a net inflow of ¥122,730,209.68 in the previous period[27] - Cash flow from investing activities resulted in a net outflow of ¥485,319,868.74, compared to a smaller outflow of ¥36,726,105.80 in the previous period[27] Inventory and Expenses - The company reported a significant increase in inventory by 41.29%, reaching ¥297,268,608.35, attributed to increased stockpiling[13] - Inventory increased to ¥297,268,608.35 from ¥210,394,935.08, reflecting a growth of about 41%[21] - Research and development expenses rose to ¥44,703,826.12, an increase of 37.52% compared to ¥32,517,062.15 in the previous period[24] - Total operating costs increased to ¥927,209,970.24, up 13.66% from ¥815,679,320.44 in the previous period[24] - The company's prepaid expenses increased to ¥55,138,376.79 from ¥16,358,996.12, reflecting a growth of about 237%[21] Profitability Metrics - The weighted average return on equity decreased to 7.93% from 18.94% in the previous year, indicating a decline in profitability[10] - The accounts receivable increased to ¥133,467,203.70 from ¥120,781,153.93, showing an increase of about 10%[21]

Core Insights - The company reported a third-quarter revenue of 327 million, representing a year-on-year increase of 4.84% [1] - The net profit for the third quarter was 33.42 million, showing a year-on-year decline of 31.08% [1] - For the first three quarters, the total revenue reached 1.073 billion, reflecting a year-on-year growth of 6.60% [1] - The net profit for the first three quarters was 132 million, which is a year-on-year decrease of 22.41% [1]